BLRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioLine RX Ltd (BLRX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, financial performance is weak, and there are no significant positive catalysts or trading signals to suggest immediate upside potential. Holding off on investment until clearer positive trends emerge is recommended.
The technical indicators for BLRX are bearish. The MACD histogram is negative and expanding downward, the RSI is neutral at 28.001, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 2.345 and S2 at 2.231. This suggests further downside risk.
The company has also enhanced patent protection for the drug.
The company reported a significant 95.9% YoY revenue decline in its FY report, with a net income drop of 83.22% YoY. The technical indicators are bearish, and there is no recent insider or hedge fund activity to support a bullish sentiment.
In 2025/Q3, BioLine RX reported a 91.36% YoY revenue decline to $427,000, a net income drop of 83.22% YoY to -$977,000, and a slight improvement in EPS to $0. Gross margin also declined to 80.33%, down 3.65% YoY. Overall, the financial performance is weak.
No recent analyst ratings or price target changes are available for BLRX.
